RNS Number : 9396M
Dechra Pharmaceuticals PLC
19 September 2023
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB0009633180
Issuer Name
DECHRA PHARMACEUTICALS PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
Barclays PLC
City of registered office (if applicable)
London
Country of registered office (if applicable)
United Kingdom
4. Details of the shareholder
|
Name |
City of registered office |
Country of registered office |
|
Barclays Capital Securities Limited |
London |
United Kingdom |
5. Date on which the threshold was crossed or reached
15-Sep-2023
6. Date on which Issuer notified
19-Sep-2023
7. Total positions of person(s) subject to the notification obligation
|
% of voting rights attached to shares (total of 8.A) |
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer |
|
|
Resulting situation on the date on which threshold was crossed or reached |
5.120000 |
1.040000 |
6.160000 |
7013448 |
|
Position of previous notification (if applicable) |
4.960000 |
1.110000 |
6.070000 |
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible) |
Number of direct voting rights (DTR5.1) |
Number of indirect voting rights (DTR5.2.1) |
% of direct voting rights (DTR5.1) |
% of indirect voting rights (DTR5.2.1) |
|
GB00BMD68046 |
|
5829807 |
|
5.120000 |
|
Sub Total 8.A |
5829807 |
5.120000% |
||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Number of voting rights that may be acquired if the instrument is exercised/converted |
% of voting rights |
|
|
|
|
|
|
|
Sub Total 8.B1 |
|
|
|
|
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Physical or cash settlement |
Number of voting rights |
% of voting rights |
|
Equity Swap |
n/a |
19/03/2025 - 23/06/2025 |
Cash |
75354 |
0.070000 |
|
Portfolio Swap |
n/a |
n/a |
Cash |
1108287 |
0.970000 |
|
Sub Total 8.B2 |
|
1183641 |
1.040000% |
||
9. Information in relation to the person subject to the notification obligation
2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
|
Ultimate controlling person |
Name of controlled undertaking |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
Barclays Plc |
Barclays Capital Securities Limited |
5.120000 |
|
6.160000% |
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
Full chain of controlled undertaking:
Barclays PLC
Barclays Bank PLC (100%)
Barclays Capital Securities Limited(100%)
12. Date of Completion
19-Sep-2023
13. Place Of Completion
London
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.